Providence Cancer Institute to hold two virtual events on the benefits of integrative medicine for patients.
Providence Cancer Institute one of only a few sites worldwide offering two new clinical trials for solid tumors and lung cancer.
Providence Cancer Institute is currently recruiting participants for three new clinical studies offered for people with HER2-neu negative breast cancer.
Leading lung cancer professionals to gather in November for premier oncology summit.
Providence gynecologic oncologist Christopher Darus, M.D. shares the latest research and promising treatments for gynecologic cancers.
Providence hematology expert offers the most updated information about lymphoma, treatment options and helpful community resources.
New investigator-initiated clinical trial available only at Providence Cancer Institute will evaluate the safety and efficacy of targeted therapy combination for treating thyroid cancer.
Providence Cancer Institute experts share their insights on recent advances in melanoma research and care, and tips on communicating with loved ones in a virtual symposium.
New Providence-sponsored study may provide new insights into the efficacy of shorter duration radiation and chemotherapy treatment before surgery for people with stage II/III rectal cancer
Results of a phase II clinical trial shows that adding an immunotherapy pill to standard pre-surgery treatment of colorectal cancer patients doubled the successful outcomes.
Two early phase trials testing the safety and tolerability of new medications may help people with sarcomas, lymphomas and other cancers.
Novel immunotherapy for pancreatic cancer employed by Providence researchers featured in New England Journal of Medicine
Adoptive cell therapy study at Providence Cancer Institute gives hope to woman with metastatic pancreatic cancer. Results may lead to new treatments and longer lives for people with advanced cancers.
Providence Cancer Institute joins oncology professionals around the world for ESMO Virtual Congress 2020, the annual meeting of the European Society for Medical Oncology, held online from September 14
A newly opened Phase 3 study at Providence Cancer Institute hopes to shed new light on the benefits of two immunotherapies, nivolumab and NKTR-214, for patients with advanced melanoma.
Dr. Jianguo Huang to lead the Preclinical Cancer Therapy Laboratory with a focus on bridging sarcoma research and immunotherapy
Providence researcher awarded National Institutes of Health grant to lead a new lab focusing on the discovery of novel inflammatory pathways in cancer that are targets for therapeutic intervention.
Learn about the health benefits of a traditional Asian diet at this free, online education event presented by Providence Cancer Institute and the Asian Health & Service Center.
Leading healthcare professionals interested in the treatment of patients with neuroendocrine tumors to gather in June for a comprehensive medical conference held in Oregon.
Two investigator-initiated trials sponsored by the Earle A. Chiles Research Institute are currently recruiting patients with either advanced HER2-positive or HR positive/HER2 negative breast cancer.
Providence researchers recruit adult patients with solid cancers for phase I clinical trial of genetically engineered, adoptively transferred T cells.